Trials / Completed
CompletedNCT05277623
Effect of Mannitol on Postreperfusion Syndrome During Living Donor Liver Transplant
Effect of Mannitol on Postreperfusion Syndrome During Living Donor Liver Transplant: a Randomized Clinical Trial
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Ain Shams University · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
Postreperfusion syndrome during living liver transplants remains a serious concern for transplant anesthesiologists. This syndrome is responsible for decreases in systemic blood pressure, systemic vascular resistance, and cardiac output and can even lead to cardiac arrest. Delayed graft function and primary graft nonfunction are closely related to postreperfusion syndrome (Therefore, attenuating the syndrome during anesthesia is of great importance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mannitol | During the anhepatic phase, the patients in the mannitol group (30) will receive 1 g/kg |
| OTHER | 0.9% normal saline | the same amount of 0.9% normal saline |
Timeline
- Start date
- 2022-04-04
- Primary completion
- 2022-11-05
- Completion
- 2022-12-10
- First posted
- 2022-03-14
- Last updated
- 2023-01-18
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05277623. Inclusion in this directory is not an endorsement.